![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Nezam Afdhal,1 Gregory T. Everson,2 Jose Luis Calleja,3 Geoffrey McCaughan,4 Jaime Bosch,5 Jill Denning,6 Diana M. Brainard,6 John G. McHutchison,6 Theo Brandt-Sarif,6 Di An,6 Michael Charlton,7 K. Rajender Reddy,8 Tarik Asselah,9 Edward Gane,10 Xavier Forns5
1Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 2University of Colorado Denver, Aurora, Colorado, USA; 3Hospital Puerta de Hierro, Madrid, Spain; 4Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia; 5Liver Unit, IDIBAPS, CIBEREHD, Barcelona, Spain; 6Gilead Sciences, Inc., Foster City, California, USA; 7Intermountain Medical Center, Murray, Utah, USA; 8University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA, 9Hopital Beaujon, INSERM U773 and University Paris-Diderot, Clichy, France; 10University of Auckland, New Zealand
![EASL1.gif](../images/042915/042915-11/EASL1.gif)
![EASL2.gif](../images/042915/042915-11/EASL2.gif)
![EASL3.gif](../images/042915/042915-11/EASL3.gif)
![EASL4.gif](../images/042915/042915-11/EASL4.gif)
![EASL5.gif](../images/042915/042915-11/EASL5.gif)
![EASL6.gif](../images/042915/042915-11/EASL6.gif)
![EASL7.gif](../images/042915/042915-11/EASL7.gif)
![EASL8.gif](../images/042915/042915-11/EASL8.gif)
![EASL9.gif](../images/042915/042915-11/EASL9.gif)
![EASL10.gif](../images/042915/042915-11/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|